Clinical Trials Directory

We are doing this study to find out if an investigational drug called belumosudil (the study drug) is an option for the treatment of chronic lung allograft dysfunction (CLAD). The study drug is taken by mouth.

We are doing this study to understand how sex hormones (chemicals that tell cells and body parts to do certain things), such as estrogens and androgens, impact skin diseases like hidradenitis suppurativa (HS). To better understand this, we are enrolling both people who have diagnosed skin diseases and healthy volunteers who have no skin issues.

We are doing this study so that we can build a risk model that helps healthcare professionals better understand which children may have more trouble after a concussion. We collect data through surveys and saliva samples over the course of 1 year. Our ultimate goal is to improve recovery and support for kids with concussions.

In this study, researchers will ask people to answer surveys over time. The surveys ask about daily life after transplant, whether they still have help from caregivers after the first few months, and if their workplace offers support or changes to help them return to work. The surveys also ask about money worries, job plans, and decisions about going back to work after the transplant.

This program lasts four to eight weeks and is designed to help people get ready to return to work after a transplant. At the first visit, an occupational therapist will do a long evaluation that may take two to four hours. During this time, the person will do activities that copy real work tasks, such as lifting, carrying, pushing, pulling, and staying active for a long time. This helps measure strength, energy, and ability to handle work duties safely. The program also includes checks of physical health, thinking skills, and mental health. The team will talk with the person about their home support, motivation to return to work, past abilities, and previous job tasks. When needed, the team will also talk with employers about job duties and possible changes to make returning to work safer and easier.

We are doing this study to compare the early treatment (before you have cancer symptoms) of Venetoclax and Obitnutuzumab (V-O) to the usual treatment of V-O after you have cancer symptoms. This study will help doctors figure out if early treatment is better, the same, or worse than the usual approach of waiting until the patient has cancer symptoms before starting treatment.

In this study, people go through a screening period and testing to learn more about their cancer. Based on special features of the cancer, called biomarkers, they are placed into one of three groups. In each group, people are also placed by chance into one of two treatment options. In all groups, one option is to receive a medicine called durvalumab. The other option is to receive durvalumab together with another medicine. The extra medicine depends on the group and may be saruparib, ceralasertib, or monalizumab. The goal of the study is to see which treatment works best for different types of cancer based on their specific features.